Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 2Hodgkin Disease 2Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 44Peripheral Blood Stem Cell Transplantation 25fludarabine phosphate 24Doxorubicin 23Etoposide 22Vincristine 21Prednisone 20Whole-Body Irradiation 19Rituximab 18Filgrastim 16Brentuximab Vedotin 15Mycophenolic Acid 14Cyclosporine 14Busulfan 14Methotrexate 12Radiotherapy 11Cytarabine 11Carboplatin 10Melphalan 9Ifosfamide 9Antilymphocyte Serum 9Tacrolimus 8Methylprednisolone 8Gemcitabine 8Bortezomib 8Dexamethasone 7Vorinostat 6Everolimus 6Crizotinib 6romidepsin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large-Cell, Anaplastic × AFM13 × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡